58546 Federal Register / Vol. 69, No. 189 / Thursday, September 30, 2004 / Notices 

1The Order to Show Cause alternates the spelling 

of the registrant’s last name between Salah and 

Saleh. Since it appears from attached 

correspondences in the investigative file that the 

common spelling of the registrant’s name is Saleh, 

the Deputy Administrator will refer to the 

registrant’s name in a similar fashion.

handle controlled substances in Ohio or 

Michigan and therefore, not entitled to 

a DEA registration in either jurisdiction. 

As a result of a finding that Dr. Phillips 

lacks any state authorization to handle 

controlled substances, the Deputy 

Administrator concludes that it is 

unnecessary to address further whether 

his DEA registration should be revoked 

based upon the public interest grounds 

asserted in the Order to Show Cause. 

See Samuel Silas Jackson, D.D.S., 67 FR 

65145 (2002); Nathaniel-Aikens-Afful, 

M.D., 62 FR 16871 (1997); Sam F. 

Moore, D.V.M., 58 FR 14428 (1993). 

Accordingly, the Deputy 

Administrator of the Drug Enforcement 

Administration, pursuant to the 

authority vested in her by 21 U.S.C. 823 

and 824 and 28 CFR 0.100(b) and 0.104, 

hereby orders that DEA Certificate of 

Registration, BP3145403, issued to 

David C. Phillips, M.D., be, and it 

hereby is, revoked. The Deputy 

Administrator further orders that any 

pending applications for renewal or 

modification of such registration be, and 

they hereby are, denied. This order is 

effective November 1, 2004.

Dated: September 8, 2004. 

Michele M. Leonhart, 

Deputy Administrator.

[FR Doc. 04–21960 Filed 9–29–04; 8:45 am] 

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated May 21, 2004, and 

published in the Federal Register on 

June 3, 2004, (69 FR 31414), Research 

Triangle Institute, Kenneth H. Davis Jr., 

Hermann Building East Institute Drive, 

P.O. Box 12194, Research Triangle Park, 

North Carolina 27709, made application 

by renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of the basic classes 

of controlled substances:

Drug Schedule 

Marihuana (7360) ......................... I 

Cocaine (9041) ............................. II 

The Institute will manufacture small 

quantities of cocaine derivates and 

marihuana derivatives for use by their 

customers primarily in analytical kits, 

reagents and standards. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Research Triangle Institute to 

manufacture the listed basic classes of 

controlled substances is consistent with 

the public interest at this time. DEA has 

investigated Research Triangle Institute 

to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed.

Dated: September 8, 2004. 

William J. Walker, 

Deputy Assistant Administrator, Office of 

Diversion Control Drug Enforcement 

Administration.

[FR Doc. 04–21951 Filed 9–29–04; 8:45 am] 

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

Import of Controlled Substances; 

Notice of Registration 

By Notice dated May 21, 2004 and 

published in the Federal Register on 

June 3, 2004, (69 FR 31413–31414), 

Research Triangle Institute, Kenneth H. 

Davis, Jr., Hermann Building East 

Institute Drive, PO Box 12194, Research 

Triangle Park, North Carolina 27709, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as an importer of 

the following basic classes of controlled 

substance:

Drug Schedule 

Marihuana (7360) ......................... I 

Cocaine (9041) ............................. II 

The company plans to import small 

quantities of the listed substances for 

the National Institute of Drug Abuse and 

other clients. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Research Triangle Institute to import the 

basic classes of controlled substances is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971, at 

this time. DEA has investigated 

Research Triangle Institute to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed.

Dated: September 15, 2004. 

William J. Walker, 

Deputy Assistant Administrator, Office of 

Diversion Control Drug Enforcement 

Administration.

[FR Doc. 04–21953 Filed 9–29–04; 8:45 am] 

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

Saeed Saleh, M.D.; Revocation of 

Registration 

On December 8, 2003, the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration (DEA), issued an Order 

to Show Cause to Saeed Seleh,1 M.D. 

(Dr. Saleh) notifying him of an 

opportunity to show cause as to why 

DEA should not revoke his Certificate of 

Registration, AS5912387, under 21 

U.S.C. 824(a)(3) and (a)(4), and deny any 

pending applications for renewal or 

modification of that registration 

pursuant to 21 U.S.C. 823(f). 

Specifically, the Order to show Cause 

alleged in relevant part, the following:

(1) Effective June 2, 2001, the State of 

Michigan, Department of Consumer and 

Industry Services, Board of Medicine 

Disciplinary Subcommittee, suspended 

Dr. Saleh’s licensure privileges. On 

September 19, 2001, the Subcommittee 

dissolved the summary suspension and 

suspended Dr. Saleh’s medical license 

for six months and one day. Because 

reinstatement of his medical license 

following the suspension was not 

automatic, Dr. Saleh was required to 

apply for reinstatement, which he failed 

to do. As of September 4, 2003, Dr. 

Saleh’s medical license was considered 

‘‘lapsed’’, as it expired on January 31, 

2003.